Quarterly ResultAug 12, 2026, 04:15 PM
Bluejay Diagnostics Q2 Net Loss $(2.32)M; Cash $9.6M
AI Summary
Bluejay Diagnostics reported a Q2 2026 net loss of $(2.32) million, an increase from $(1.96) million in Q2 2025. Despite the increased loss, the company's cash and cash equivalents significantly rose to $9.6 million as of June 30, 2026, primarily due to approximately $8.5 million in gross proceeds from a June 2026 private placement. Bluejay also announced the successful completion of patient enrollment for its SYMON-II clinical validation study for the Symphony IL-6 test, targeting an FDA 510(k) submission in the first half of 2027, but noted substantial doubt about its ability to continue as a going concern without further capital.
Key Highlights
- Reported Q2 2026 net loss of $(2.32) million, compared to $(1.96) million in Q2 2025.
- Cash and cash equivalents increased to $9.6 million as of June 30, 2026, from $5.2 million at Dec 31, 2025.
- Gross proceeds of approximately $8.5 million were raised from the June 2026 private placement.
- Successfully completed patient enrollment for the SYMON-II clinical validation study for its Symphony IL-6 test.
- Aims for FDA 510(k) regulatory application for Symphony IL-6 test in the first half of 2027.
- R&D expenses increased to $1.44 million in Q2 2026 from $0.89 million in Q2 2025.
- Company expects to need $10.0 million to $14.0 million in additional capital by end of FY2027.
- A 1-for-4 reverse stock split was effective January 29, 2026.
Price Impact
More from BJDX